The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect. Therapeutic Solutions International, Inc. (TSOI), announced its breast cancer focused immunotherapy subsidiary company, Res Nova Bio, has recruited internationally renowned medical doctor George Delgado to its Scientific Advisory Board.

Dr. Delgado is an expert in the biology of pregnancy and the abortion pill, being the founder of ?Abortion Pill Reversal? and having been the first to publish in the peer-reviewed literature successful reversal of mifepristone administration using progesterone treatment. Res Nova is developing FloraStilbene?, a proprietary formulation of RU-486 and pterostilbene which has been shown to overcome tumor associated immune suppression and increases responsiveness to chemotherapy and immunotherapy.

The Company has signed a collaborative agreement with Cure Stat Rx, a premiere compounding pharmacy and plans to eventually commercialize through the 505b2 pathway. Dr. Delgado received his undergraduate degree at St. Mary?s College of California where he graduated summa cum laude and received the biology department?s top honor ?

the Carlos Freitas Award. He attended medical school at UC Davis and completed his residency training at Santa Monica Hospital/UCLA. He has given numerous presentations to various groups on medical and bioethical topics.